BACKGROUND/AIMS: We evaluated the efficacy and safety of bevacizumab for metastatic @entity14 @entity1 . METHODOLOGY: All unresectable metastatic @entity14 @entity1 who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy. The primary end points were Progression Free Survival (PFS) and @entity1349 ( @entity1349 ). The secondary end points were adverse events. RESULTS: A total of 101 @entity1 were enrolled in the study. The primary @entity5 site was the colon in 53 @entity1 and the rectum in 48 @entity1 . The most common metastatic sites were the liver (63.4%), lung (31%), and peritoneum (10%). In first-line therapy, 76 (75.2%) @entity1 received the FOLFOX regimen. Among these @entity1 , 33 (43.4%) @entity1 received FOLFOX alone, and 43 (56.6%) received FOLFOX plus bevacizumab. The addition of bevacizumab to first-line chemotherapy was associated with increases in median PFS (12.5 vs. 6.0 months; P = .00001) and median @entity1349 (24.0 vs. 16.0 months; P = 0.0221). The risks of adverse events were not significantly increased with the addition of bevacizumab. CONCLUSIONS: The addition of bevacizumab to first-line therapy in @entity14 @entity1 provided clinically significant @entity1 benefit, including statistically significant improvement in @entity1349 and a favorable tolerability profile.

Addition of Bevacizumab to First-Line Chemotherapy for Metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall Survival']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer']
